Literature DB >> 22349567

Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.

Elma E Chang1, Jeffrey L Goldberg.   

Abstract

Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve. Clinically, our only method of slowing glaucomatous loss of vision is to reduce intraocular pressure (IOP), but lowering IOP is only partially effective and does not address the underlying susceptibility of RGCs to degeneration. We review the recent steps forward in our understanding of the pathophysiology of glaucoma and discuss how this understanding has given us a next generation of therapeutic targets by which to maintain RGC survival, protect or rebuild RGC connections in the retina and brain, and enhance RGC function.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349567      PMCID: PMC3343191          DOI: 10.1016/j.ophtha.2011.11.003

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  38 in total

1.  Reversal of retinal ganglion cell dysfunction after surgical reduction of intraocular pressure.

Authors:  Mitra Sehi; Dilraj S Grewal; Margot L Goodkin; David S Greenfield
Journal:  Ophthalmology       Date:  2010-10-08       Impact factor: 12.079

2.  Invulnerability of retinal ganglion cells to NMDA excitotoxicity.

Authors:  E M Ullian; W B Barkis; S Chen; J S Diamond; B A Barres
Journal:  Mol Cell Neurosci       Date:  2004-08       Impact factor: 4.314

Review 3.  Blood pressure and glaucoma.

Authors:  V P Costa; E S Arcieri; A Harris
Journal:  Br J Ophthalmol       Date:  2009-03-30       Impact factor: 4.638

Review 4.  Diagnosing glaucoma progression.

Authors:  Robert T Chang; Donald L Budenz
Journal:  Int Ophthalmol Clin       Date:  2008

5.  Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage.

Authors:  Iok-Hou Pang; Elaine C Johnson; Lijun Jia; William O Cepurna; Allan R Shepard; Mark R Hellberg; Abbot F Clark; John C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-04       Impact factor: 4.799

6.  Changes in visual function after intraocular pressure reduction using antiglaucoma medications.

Authors:  T S Prata; M V Piassi; L A S Melo
Journal:  Eye (Lond)       Date:  2008-08-01       Impact factor: 3.775

7.  Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma.

Authors:  Thomas V Johnson; Natalie D Bull; David P Hunt; Nephtali Marina; Stanislav I Tomarev; Keith R Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

8.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

9.  The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.

Authors:  Robert N Weinreb; Paul L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04       Impact factor: 4.799

10.  Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine.

Authors:  Melinda Fitzgerald; Sophie C Payne; Carole A Bartlett; Lauren Evill; Alan R Harvey; Sarah A Dunlop
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-27       Impact factor: 4.799

View more
  112 in total

Review 1.  Glaucoma management: relative value and place in therapy of available drug treatments.

Authors:  Deepak Sambhara; Ahmad A Aref
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

2.  Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis.

Authors:  Arzu Toruk Aksar; Nursen Yuksel; Mustafa Gok; Mustafa Cekmen; Yusuf Caglar
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

3.  Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome.

Authors:  Thomas V Johnson; Nicholas W DeKorver; Victoria A Levasseur; Andrew Osborne; Alessia Tassoni; Barbara Lorber; Janosch P Heller; Rafael Villasmil; Natalie D Bull; Keith R Martin; Stanislav I Tomarev
Journal:  Brain       Date:  2013-10-30       Impact factor: 13.501

4.  Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma.

Authors:  Vincenzo Parisi; Marco Centofanti; Lucia Ziccardi; Lucia Tanga; Manuele Michelessi; Gloria Roberti; Gianluca Manni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-26       Impact factor: 3.117

5.  Pigment epithelium-derived factor protects retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction.

Authors:  Shu-Wei Tian; Yuan Ren; Jin-Zhi Pei; Bai-Chao Ren; Yuan He
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

6.  Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes.

Authors:  Simon Kaja; Andrew J Payne; Yuliya Naumchuk; Deborah Levy; Danish H Zaidi; Alexa M Altman; Saba Nawazish; Jasleen K Ghuman; Bryan C Gerdes; Mark A Moore; Peter Koulen
Journal:  Exp Eye Res       Date:  2015-06-03       Impact factor: 3.467

7.  Differential up-regulation of Vesl-1/Homer 1 protein isoforms associated with decline in visual performance in a preclinical glaucoma model.

Authors:  Simon Kaja; Yuliya Naumchuk; Stephanie L Grillo; Priscilla K Borden; Peter Koulen
Journal:  Vision Res       Date:  2013-11-09       Impact factor: 1.886

8.  Genetic access to neurons in the accessory optic system reveals a role for Sema6A in midbrain circuitry mediating motion perception.

Authors:  Brendan N Lilley; Shai Sabbah; John L Hunyara; Katherine D Gribble; Timour Al-Khindi; Jiali Xiong; Zhuhao Wu; David M Berson; Alex L Kolodkin
Journal:  J Comp Neurol       Date:  2018-11-11       Impact factor: 3.215

9.  Applying proteomics to research for optic nerve regeneration in glaucoma: what's on the horizon?

Authors:  Gülgün Tezel
Journal:  Expert Rev Proteomics       Date:  2016-09-24       Impact factor: 3.940

10.  Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

Authors:  Jessica A Cooke; Jason S Meyer
Journal:  Curr Ophthalmol Rep       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.